Study FVF2598g was an ongoing Phase III study designed to assess the efficacy and safety of intravitreal injections of ranibizumab administered monthly compared with sham injections administered monthly in subjects with angiographically determined, minimally classic or occult subfoveal neovascular AMD. Data show that ranibizumab was safe and efficacious in subjects with subfoveal CNV due to AMD.